DXCMHealthcare · Medical DevicesThe 28 Wall Street analysts covering DexCom, Inc. hold a median 12-month price target of $93 — +3.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 13 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores DexCom, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (57): The shares have been drifting down relative to others.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DXCM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +3.6% from it.
Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Argus Research | Maintains | Buy | $86 → $96 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | $82 → $90 |
| 31 July 2026 | Benchmark | Maintains | Buy | $77 → $82 |
| 31 July 2026 | BTIG | Maintains | Buy | $80 → $90 |
| 31 July 2026 | Citigroup | Maintains | Buy | $84 → $88 |
| 31 July 2026 | JP Morgan | Maintains | Neutral | $65 → $82 |
| 31 July 2026 | Mizuho | Maintains | Outperform | $90 → $95 |
| 31 July 2026 | Piper Sandler | Reiterates | Overweight | $88 → $95 |
| 31 July 2026 | RBC Capital | Maintains | Outperform | $85 → $90 |
| 31 July 2026 | Stifel | Maintains | Buy | $90 → $95 |
| 31 July 2026 | Truist Securities | Maintains | Buy | $87 → $93 |
| 31 July 2026 | Wells Fargo | Maintains | Overweight | $85 → $90 |
| 28 July 2026 | UBS | Reinstates | Buy | $96 |
| 16 July 2026 | Truist Securities | Maintains | Buy | $80 → $87 |
| 16 July 2026 | Truist Securities | Maintains | Buy | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $85 → $90 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 23 June 2026 | Deutsche Bank | Initiates | Buy | $86 |
| 23 June 2026 | Deutsche Bank | Initiates | Buy | — |
| 15 June 2026 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DXCM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 23% of US stocks
Cheaper than 19% of US stocks
Cheaper than 8% of US stocks
Cheaper than 13% of US stocks
Higher than 60% of US stocks
Higher than 71% of US stocks
Higher than 77% of US stocks
Higher than 83% of US stocks
Higher than 82% of US stocks
Higher than 91% of US stocks
Higher than 92% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DexCom, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights DexCom (DXCM) as a strong growth stock, using its Zacks Style Scores feature to identify the company as a top growth pick. The piece is part of Zacks Premium's research service for finding strong stocks.
Why it matters — DXCM watchers would care because the company is being singled out as a strong growth stock by a research service's screening methodology.
Zacks Research reviews whether DXCM stock is worth buying, noting that broader continuous glucose monitor (CGM) coverage, the G7 15 Day rollout, and rising margins support growth, while a premium valuation, competition, and litigation temper upside.
Why it matters — A DXCM watcher would care because the item weighs the company's growth drivers against the risks of valuation, competition, and legal issues that could affect its outlook.
DexCom raised its 2026 revenue and margin outlook, citing improved profitability driven by efficiencies from the G7 15 Day sensor. The company noted that foreign exchange impacts and transition costs remain key factors to watch.
Why it matters — The raised 2026 outlook points to stronger margin momentum for DexCom, something DXCM watchers would track alongside ongoing FX and transition-cost headwinds.
Zacks reports that DexCom shares have rallied 52.5% over the past three months, supported by earnings growth and margin improvements, though the stock now faces headwinds including a premium valuation, competitive pressures, and ongoing litigation.
Why it matters — DXCM watchers would care because the article highlights both the strong recent performance and the key risks that could determine whether the stock can sustain its climb.
DXCM shares have risen nearly 35% year-to-date in 2026, with the rebound supported by stronger growth, adoption of the G7 15 Day sensor, and broader CGM access. Competition and reimbursement pressures are highlighted as key risks to the uptrend.
Why it matters — DXCM watchers would care because the article assesses whether the company's strong 2026 rebound can be sustained amid growth drivers and lingering competitive and reimbursement risks.
The 28 Wall Street analysts covering DexCom, Inc. have a median 12-month price target of $93, with estimates ranging from $79 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering DexCom, Inc., 25 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DexCom, Inc. 98 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, DexCom, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +3.6% from the last close, and Ticker Nerd's factor model ranks DexCom, Inc. 98 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DexCom, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DXCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $115 over the next 12 months.
DexCom, Inc. returned +12.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
DexCom, Inc. is a medical device company focused on continuous glucose monitoring systems for people living with diabetes and related metabolic conditions.
The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Here's Why DexCom (DXCM) is a Strong Growth Stock". Zacks Investment Research highlights DexCom (DXCM) as a strong growth stock, using its Zacks Style Scores feature to identify the company as a top growth pick. The piece is part of Zacks Premium's research service for finding strong stocks.
DexCom, Inc. is a medical device company focused on continuous glucose monitoring systems for people living with diabetes and related metabolic conditions. The company develops wearable sensors, receivers, mobile apps, cloud-based data sharing tools, and software that provide real-time glucose insights and support everyday diabetes management. Its product lineup includes CGM systems such as Dexcom G7 and Dexcom G6, along with offerings like Dexcom ONE, Stelo, and remote monitoring services that help users, caregivers, and clinicians track glucose trends more easily. DexCom serves individuals, healthcare providers, endocrinologists, diabetes educators, and clinical care networks across the United States and international markets. Headquartered in San Diego, California, DexCom plays an important role in diabetes technology by combining biosensing hardware with digital health tools to improve glucose visibility and care coordination.
CEO Mr. Jacob Steven Leach · 11,000 employees · United States · https://www.dexcom.com